MX2015006738A - Anticuerpos monoclonales humanizados contra la proteina c activada y sus usos. - Google Patents
Anticuerpos monoclonales humanizados contra la proteina c activada y sus usos.Info
- Publication number
- MX2015006738A MX2015006738A MX2015006738A MX2015006738A MX2015006738A MX 2015006738 A MX2015006738 A MX 2015006738A MX 2015006738 A MX2015006738 A MX 2015006738A MX 2015006738 A MX2015006738 A MX 2015006738A MX 2015006738 A MX2015006738 A MX 2015006738A
- Authority
- MX
- Mexico
- Prior art keywords
- antibody
- seq
- cell
- residue
- apc
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
- G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
- G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
- G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
- G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
- G01N2333/96433—Serine endopeptidases (3.4.21)
- G01N2333/96441—Serine endopeptidases (3.4.21) with definite EC number
- G01N2333/96461—Protein C (3.4.21.69)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261731368P | 2012-11-29 | 2012-11-29 | |
| PCT/US2013/072137 WO2014085527A1 (en) | 2012-11-29 | 2013-11-27 | Humanized monoclonal antibodies against activated protein c and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2015006738A true MX2015006738A (es) | 2015-08-05 |
Family
ID=50828440
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015006738A MX2015006738A (es) | 2012-11-29 | 2013-11-27 | Anticuerpos monoclonales humanizados contra la proteina c activada y sus usos. |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | USRE49099E1 (enExample) |
| EP (1) | EP2925360A4 (enExample) |
| JP (1) | JP2016501875A (enExample) |
| KR (1) | KR20150088853A (enExample) |
| CN (1) | CN104936618A (enExample) |
| AR (1) | AR093672A1 (enExample) |
| AU (1) | AU2013352260A1 (enExample) |
| BR (1) | BR112015012458A2 (enExample) |
| CA (1) | CA2892748A1 (enExample) |
| HK (1) | HK1215174A1 (enExample) |
| IL (1) | IL238920A0 (enExample) |
| MX (1) | MX2015006738A (enExample) |
| RU (1) | RU2015125343A (enExample) |
| SG (1) | SG11201504035PA (enExample) |
| TW (1) | TW201437229A (enExample) |
| UY (1) | UY35160A (enExample) |
| WO (1) | WO2014085527A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015179435A1 (en) * | 2014-05-19 | 2015-11-26 | Bayer Healthcare Llc | Optimized humanized monoclonal antibodies against activated protein c and uses thereof |
| US11077187B2 (en) * | 2015-11-17 | 2021-08-03 | Oklahoma Medical Research Foundation | Epitope of optimized humanized monoclonal antibodies against activated protein C and uses thereof |
| WO2020051277A1 (en) | 2018-09-06 | 2020-03-12 | Board Of Regents, The University Of Texas System | Treatment and prevention of hemophilic arthropathy with an antibody against endothelial cell protein c receptor (epcr) |
| CN115611986B (zh) * | 2021-07-13 | 2025-08-12 | 上海莱士血液制品股份有限公司 | 针对人活化蛋白c的单克隆抗体及其制备和应用 |
| KR20240152428A (ko) * | 2022-03-04 | 2024-10-21 | 주식회사 코애귤런트테라퓨틱스 | 활성화된 단백질 c에 대한 인간 항체 및 이의 용도 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5202253A (en) | 1988-12-30 | 1993-04-13 | Oklahoma Medical Research Foundation | Monoclonal antibody specific for protein C and antibody purification method |
| US7247453B1 (en) | 1988-12-30 | 2007-07-24 | Oklahoma Medical Research Foundation | Calcium binding recombinant antibody against protein C |
| US5279956A (en) | 1991-06-24 | 1994-01-18 | The Scripps Research Institute | Activated protein C polypeptides and anti-peptide antibodies, diagnostic methods and systems for inhibiting activated protein C |
| US5695993A (en) | 1994-08-12 | 1997-12-09 | Oklahoma Medical Research Foundation | Cloning and regulation of an endothelial cell protein C/activated protein C receptor |
| PT1754718E (pt) | 1996-04-24 | 2011-07-13 | Univ Michigan | Factor viii resistente à inactivação |
| US6953568B1 (en) | 1998-08-25 | 2005-10-11 | Oklahoma Medical Research Foundation | Targeting of molecules to large vessel endothelium using EPCR |
| DE60141844D1 (de) | 2000-10-02 | 2010-05-27 | Oklahoma Med Res Found | Assay zum schnellen nachweis vom humanen aktivierten protein c und hochspezifischer monoklonaler antikörper dagegen |
| US20030203355A1 (en) | 2002-04-24 | 2003-10-30 | Los Alamos National Laboratory | Fluorobodies: binding ligands with intrinsic fluorescence |
| US20090068178A1 (en) * | 2002-05-08 | 2009-03-12 | Genentech, Inc. | Compositions and Methods for the Treatment of Tumor of Hematopoietic Origin |
| TW200407335A (en) | 2002-07-22 | 2004-05-16 | Chugai Pharmaceutical Co Ltd | Non-neutralizing antibody to inhibit the inactivation of activated protein C |
| US7662387B2 (en) | 2003-02-20 | 2010-02-16 | Seattle Genetics | Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders |
| US7423128B2 (en) | 2004-11-03 | 2008-09-09 | Amgen Fremont Inc. | Anti-properdin antibodies, and methods for making and using same |
| CA2591665C (en) | 2004-12-20 | 2015-05-05 | Crucell Holland B.V. | Binding molecules capable of neutralizing west nile virus and uses thereof |
| JP4829609B2 (ja) | 2004-12-22 | 2011-12-07 | 独立行政法人科学技術振興機構 | ヒト抗体酵素およびその生産方法 |
| PL1963368T6 (pl) * | 2005-12-13 | 2021-02-08 | Eli Lilly And Company | Przeciwciała anty-IL-17 |
| SI3219328T1 (sl) * | 2005-12-29 | 2020-10-30 | Janssen Biotech, Inc. | Človeška protitelesa proti-IL-23, sestavki, postopki in uporabe |
| NZ574804A (en) | 2006-08-11 | 2012-02-24 | Schering Corp | Antibodies to il-17a |
| US8039597B2 (en) | 2007-09-07 | 2011-10-18 | Agensys, Inc. | Antibodies and related molecules that bind to 24P4C12 proteins |
| AR068767A1 (es) | 2007-10-12 | 2009-12-02 | Novartis Ag | Anticuerpos contra esclerostina, composiciones y metodos de uso de estos anticuerpos para tratar un trastorno patologico mediado por esclerostina |
| BRPI0818865A2 (pt) | 2007-10-26 | 2015-05-05 | Oklahoma Med Res Found | Anticorpos monoclonais contra proteína c ativada. |
| US20100291106A1 (en) | 2009-05-06 | 2010-11-18 | Novartis Ag | Compositions and methods for antibodies targeting complement protein c3b |
| GB201011771D0 (en) | 2010-07-13 | 2010-08-25 | Bioinvent Int Ab | Biological material and particular uses thereof |
-
2013
- 2013-11-27 CN CN201380071700.3A patent/CN104936618A/zh active Pending
- 2013-11-27 US US16/419,319 patent/USRE49099E1/en active Active
- 2013-11-27 SG SG11201504035PA patent/SG11201504035PA/en unknown
- 2013-11-27 US US14/443,696 patent/US9657111B2/en not_active Ceased
- 2013-11-27 AU AU2013352260A patent/AU2013352260A1/en not_active Abandoned
- 2013-11-27 MX MX2015006738A patent/MX2015006738A/es unknown
- 2013-11-27 CA CA2892748A patent/CA2892748A1/en not_active Abandoned
- 2013-11-27 HK HK16103170.8A patent/HK1215174A1/zh unknown
- 2013-11-27 WO PCT/US2013/072137 patent/WO2014085527A1/en not_active Ceased
- 2013-11-27 RU RU2015125343A patent/RU2015125343A/ru not_active Application Discontinuation
- 2013-11-27 KR KR1020157016868A patent/KR20150088853A/ko not_active Withdrawn
- 2013-11-27 JP JP2015545419A patent/JP2016501875A/ja active Pending
- 2013-11-27 BR BR112015012458A patent/BR112015012458A2/pt not_active Application Discontinuation
- 2013-11-27 EP EP13857737.4A patent/EP2925360A4/en not_active Ceased
- 2013-11-29 TW TW102143763A patent/TW201437229A/zh unknown
- 2013-11-29 UY UY0001035160A patent/UY35160A/es unknown
- 2013-11-29 AR ARP130104418A patent/AR093672A1/es unknown
-
2015
- 2015-05-20 IL IL238920A patent/IL238920A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2925360A1 (en) | 2015-10-07 |
| US20150322164A1 (en) | 2015-11-12 |
| KR20150088853A (ko) | 2015-08-03 |
| RU2015125343A (ru) | 2017-01-11 |
| WO2014085527A1 (en) | 2014-06-05 |
| US9657111B2 (en) | 2017-05-23 |
| CA2892748A1 (en) | 2014-06-05 |
| EP2925360A4 (en) | 2016-07-13 |
| AR093672A1 (es) | 2015-06-17 |
| JP2016501875A (ja) | 2016-01-21 |
| HK1215174A1 (zh) | 2016-08-19 |
| TW201437229A (zh) | 2014-10-01 |
| SG11201504035PA (en) | 2015-06-29 |
| IL238920A0 (en) | 2015-07-30 |
| AU2013352260A1 (en) | 2015-06-11 |
| UY35160A (es) | 2014-06-30 |
| BR112015012458A2 (pt) | 2018-02-06 |
| CN104936618A (zh) | 2015-09-23 |
| USRE49099E1 (en) | 2022-06-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7819160B2 (ja) | マトリプターゼ及びｕ‐プラスミノーゲン活性化因子の基質及び他の切断可能部分、並びにその使用方法 | |
| CN113271956B (zh) | 基质金属蛋白酶可裂解的和丝氨酸或半胱氨酸蛋白酶可裂解的底物及其使用方法 | |
| CN106163556B (zh) | 基质金属蛋白酶底物和其它可切割部分及其使用方法 | |
| DK2521568T3 (en) | PLASMACALLIC CLEANING PROTEINS | |
| US9574013B2 (en) | Antibodies against factor XII and uses thereof | |
| AU2018300237A1 (en) | Anti-CD166 antibodies and uses thereof | |
| CN105658240A (zh) | 用于缀合可活化抗体的组合物和方法 | |
| CN107531758A (zh) | 基质金属蛋白酶可切割且丝氨酸蛋白酶可切割底物及其使用方法 | |
| US9657111B2 (en) | Humanized monoclonal antibodies against activated protein C and uses thereof | |
| TW202342523A (zh) | 抗Ｎｅｃｔｉｎ－４抗體和雙特異性抗體 | |
| US11077187B2 (en) | Epitope of optimized humanized monoclonal antibodies against activated protein C and uses thereof | |
| WO2015179435A1 (en) | Optimized humanized monoclonal antibodies against activated protein c and uses thereof | |
| TWI857319B (zh) | 針對人活化蛋白c的單株抗體及其製備和應用 | |
| CN114080396B (zh) | 抗-angpt2抗体 | |
| EP4431526A1 (en) | Anti-gpvi antibodies and functional fragments thereof | |
| RU2824515C1 (ru) | Моноклональное антитело к активированному белку с человека и его получение и применение | |
| TW201609809A (zh) | 活化蛋白ｃ之最佳化人化單株抗體及其用途 | |
| HK40081269A (en) | Monoclonal antibody against human activated protein c and preparation and use thereof | |
| TW201609808A (zh) | 抗活化蛋白ｃ之人類化單株抗體之抗原決定區基因定位及其用途 |